Active, not recruitingPhase 2NCT06256328
A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)
Studying NON RARE IN EUROPE: Adenocarcinoma of stomach
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ono Pharmaceutical Co. Ltd
- Principal Investigator
- Project LeaderOno Pharmaceutical Co. Ltd
- Intervention
- ONO-4578(drug)
- Enrollment
- 226 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2027
Study locations (30)
- Aichi Cancer Center Hospital, Nagoya, Aichi-ken, Japan
- National Cancer Center Hospital East, Kashiwa-shi, Chiba, Japan
- Matsuyama Red Cross Hospital, Matsuyama, Ehime, Japan
- NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan
- Kyushu University Hospital, Fukuoka, Fukuoka, Japan
- NHO Kyushu Cancer Center, Fukuoka, Fukuoka, Japan
- JCHO Kyushu Hospital, Yahatanishi-ku, Kitakyusyu-shi, Fukuoka, Japan
- Gunma Prefectural Cancer Center, Ota-shi, Gunma, Japan
- Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Hiroshima, Japan
- Hyogo Cancer Center, Akashi-shi, Hyōgo, Japan
- JOHAS Kansai Rosai Hospital, Amagasaki-shi, Hyōgo, Japan
- Kobe City Hospital Organization Kobe City Medical Center General Hospital, Kobe, Hyōgo, Japan
- Ibaraki Prefectural Central Hospital, Kasama-shi, Ibaraki, Japan
- Ishikawa Prefectural Central Hospital, Kanazawa, Ishikawa-ken, Japan
- Iwate Medical University Hospital, Yahaba-cho, Shiwa-gun, Iwate, Japan
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06256328 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Adenocarcinoma of stomach
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07431281Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2AstraZeneca
- ACTIVE NOT RECRUITINGNCT07448493Local Treatment Strategies for Brain Metastases of Gastric and Esophageal CancerBlokhin's Russian Cancer Research Center
- RECRUITINGPHASE1, PHASE2NCT07262619EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) TumorsEikon Therapeutics
- RECRUITINGPHASE2NCT07070466Ivonescimab in Comb. With FOLFOX in Advanced HER2 Neg. GEAMassachusetts General Hospital
- RECRUITINGPHASE2NCT07102901Safety and Efficacy of SHR2554 Combined With Other Antitumor Therapies in Gastric or Gastro-oesophageal Junction AdenocarcinomaJiangsu HengRui Medicine Co., Ltd.
- RECRUITINGPHASE2NCT07212933The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled TrialChinese PLA General Hospital
- RECRUITINGNCT07032961A Cohort Study of Mobile Capsule Gastroscopy for Gastric Pathologies ScreeningNanfang Hospital, Southern Medical University
- RECRUITINGPHASE1, PHASE2NCT06710756Lead-212 PSV359 Therapy for Patients With Solid TumorsPerspective Therapeutics
See all trials for NON RARE IN EUROPE: Adenocarcinoma of stomach →